Optimizing Intrapleural Bevacizumab Dosing in Non-Small-Cell Lung Cancer-Mediated Malignant Pleural Effusion: Less is More

Abstract

Aim: Intrapleural infusion of bevacizumab (BEV) is an emerging clinical treatment for malignant pleural effusion, but many details of usage need to be determined, especially for the effective dose. Patients & methods: We performed a retrospective study of the records of malignant pleural effusion patients from non-small-cell lung cancer who underwent intrapleural infusion of BEV. According to the BEV dose commonly used in clinical, patients were allocated into either low-dose group or high-dose group. Results: A total of 71 patients were enrolled in this study. Administration with intrapleural BEV in low dose has less toxicity. For survival data, low- and high-dose groups have no difference. Conclusion: Lower rates of serious BEV-related toxicities and similar survival date are noted when lower dosages are used without diminishing positive clinical impact.

Keywords::

• adverse events
• bevacizumab dose
• intrapleural
• malignant pleural effusion
• NSCLC
• outcomes

Supplementary data

To view the supplementary data that accompany this paper, please visit the journal website at: www.tandfonline.com/doi/suppl/10.2217/fon-2018-0089

Acknowledgements

The authors thank Innovation Project of Shandong Academy of Medical Science for support.

Financial & competing interests disclosure

This study was funded by a grant from the National Health and Family Planning Commission of China (grant number: 201402011), Shandong Provincial Natural Science Foundation (grant number: ZR2015HZ004) and supported by a grant from the National Natural Science Foundation of China (grant number: 81472812). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

Due to the retrospective nature of the study, informed consent was waived. The study was approved by the committee of Shandong Cancer Hospital, Jinan, China.

Additional information

Funding

This study was funded by a grant from the National Health and Family Planning Commission of China (grant number: 201402011), Shandong Provincial Natural Science Foundation (grant number: ZR2015HZ004) and supported by a grant from the National Natural Science Foundation of China (grant number: 81472812). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.